阿帕他赛和托法替尼治疗难治性肉样瘤病:药物存活率、安全性和治疗反应。

IF 3.4 4区 医学 Q2 RHEUMATOLOGY
Henrik Christian Bidstrup Leffers, Bo Baslund, Jesper Lindhardsen, Sophine Boysen Krintel, Niels Graudal
{"title":"阿帕他赛和托法替尼治疗难治性肉样瘤病:药物存活率、安全性和治疗反应。","authors":"Henrik Christian Bidstrup Leffers, Bo Baslund, Jesper Lindhardsen, Sophine Boysen Krintel, Niels Graudal","doi":"10.55563/clinexprheumatol/mmzdlj","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe drug survival, safety and treatment response in sarcoidosis patients treated with abatacept or tofacitinib in routine care.</p><p><strong>Methods: </strong>We identified 41 sarcoidosis patients treated with abatacept and 12 patients treated with tofacitinib. Of the patients treated with tofacitinib 83% had previously been treated with abatacept. Drug survival and reasons for discontinuation of treatment was investigated. Treatment response was evaluated at least once within the first 6 months of treatment by at least one trained clinician and classified as responder or non-responder. No direct comparison of drugs was made.</p><p><strong>Results: </strong>Median (range) disease duration was 3.5 (1-27) and 3 (1-16) years for abatacept and tofacitinib. The patients had previously received a median of 1 DMARD and 1 biological DMARD in both groups. Nearly all patients had been treated with at least one TNFi (95%/92 %). After 6 months, 90% (95%CI 85-90%) of the 41 patients in the abatacept group and 89% (79-99%) of the 12 patients in the tofacitinib group-maintained treatment. At 12 months, it was 80% (73-87%) and 74% (58-90%). No serious adverse events were recorded. For abatacept and tofacitinib 71% and 67% of patients were characterised as responders. In both treatment groups, there was a significant reduction in prednisolone dosage and levels of soluble IL2-receptor at all time points.</p><p><strong>Conclusions: </strong>Sarcoidosis patients treated with abatacept and tofacitinib had long drug survival, achieved high response rates. Both drugs represent good and safe therapeutic options in sarcoidosis patient's refractory to previous TNFi therapy.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response.\",\"authors\":\"Henrik Christian Bidstrup Leffers, Bo Baslund, Jesper Lindhardsen, Sophine Boysen Krintel, Niels Graudal\",\"doi\":\"10.55563/clinexprheumatol/mmzdlj\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To describe drug survival, safety and treatment response in sarcoidosis patients treated with abatacept or tofacitinib in routine care.</p><p><strong>Methods: </strong>We identified 41 sarcoidosis patients treated with abatacept and 12 patients treated with tofacitinib. Of the patients treated with tofacitinib 83% had previously been treated with abatacept. Drug survival and reasons for discontinuation of treatment was investigated. Treatment response was evaluated at least once within the first 6 months of treatment by at least one trained clinician and classified as responder or non-responder. No direct comparison of drugs was made.</p><p><strong>Results: </strong>Median (range) disease duration was 3.5 (1-27) and 3 (1-16) years for abatacept and tofacitinib. The patients had previously received a median of 1 DMARD and 1 biological DMARD in both groups. Nearly all patients had been treated with at least one TNFi (95%/92 %). After 6 months, 90% (95%CI 85-90%) of the 41 patients in the abatacept group and 89% (79-99%) of the 12 patients in the tofacitinib group-maintained treatment. At 12 months, it was 80% (73-87%) and 74% (58-90%). No serious adverse events were recorded. For abatacept and tofacitinib 71% and 67% of patients were characterised as responders. In both treatment groups, there was a significant reduction in prednisolone dosage and levels of soluble IL2-receptor at all time points.</p><p><strong>Conclusions: </strong>Sarcoidosis patients treated with abatacept and tofacitinib had long drug survival, achieved high response rates. Both drugs represent good and safe therapeutic options in sarcoidosis patient's refractory to previous TNFi therapy.</p>\",\"PeriodicalId\":10274,\"journal\":{\"name\":\"Clinical and experimental rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and experimental rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.55563/clinexprheumatol/mmzdlj\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/mmzdlj","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的描述在常规护理中接受阿帕他赛或托法替尼治疗的肉样瘤患者的药物存活率、安全性和治疗反应:我们确定了41名接受阿帕他赛治疗的肉样瘤患者和12名接受托法替尼治疗的患者。在接受托法替尼治疗的患者中,83%曾接受过阿帕塞普治疗。对药物存活率和中断治疗的原因进行了调查。在治疗的前6个月内,至少由一名受过培训的临床医生对治疗反应进行一次评估,并将其分为应答者和非应答者。没有对药物进行直接比较:阿帕他赛和托法替尼的中位病程(范围)分别为3.5年(1-27年)和3年(1-16年)。两组患者之前接受过的治疗中位数分别为1种DMARD和1种生物DMARD。几乎所有患者都接受过至少一种TNFi治疗(95%/92%)。6个月后,阿帕替尼组41名患者中的90%(95%CI 85-90%)和托法替尼组12名患者中的89%(79-99%)继续接受治疗。12个月时,维持治疗的比例分别为80%(73-87%)和74%(58-90%)。没有严重不良事件的记录。阿帕他赛和托法替尼分别有71%和67%的患者被认定为应答者。在两个治疗组中,泼尼松龙用量和可溶性IL2-受体水平在所有时间点均显著降低:结论:接受阿帕他赛普和托法替尼治疗的肉样瘤患者药物存活期长,应答率高。这两种药物对于既往TNFi疗法难治的肉样瘤病患者来说,是良好而安全的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response.

Objectives: To describe drug survival, safety and treatment response in sarcoidosis patients treated with abatacept or tofacitinib in routine care.

Methods: We identified 41 sarcoidosis patients treated with abatacept and 12 patients treated with tofacitinib. Of the patients treated with tofacitinib 83% had previously been treated with abatacept. Drug survival and reasons for discontinuation of treatment was investigated. Treatment response was evaluated at least once within the first 6 months of treatment by at least one trained clinician and classified as responder or non-responder. No direct comparison of drugs was made.

Results: Median (range) disease duration was 3.5 (1-27) and 3 (1-16) years for abatacept and tofacitinib. The patients had previously received a median of 1 DMARD and 1 biological DMARD in both groups. Nearly all patients had been treated with at least one TNFi (95%/92 %). After 6 months, 90% (95%CI 85-90%) of the 41 patients in the abatacept group and 89% (79-99%) of the 12 patients in the tofacitinib group-maintained treatment. At 12 months, it was 80% (73-87%) and 74% (58-90%). No serious adverse events were recorded. For abatacept and tofacitinib 71% and 67% of patients were characterised as responders. In both treatment groups, there was a significant reduction in prednisolone dosage and levels of soluble IL2-receptor at all time points.

Conclusions: Sarcoidosis patients treated with abatacept and tofacitinib had long drug survival, achieved high response rates. Both drugs represent good and safe therapeutic options in sarcoidosis patient's refractory to previous TNFi therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.10
自引率
18.90%
发文量
377
审稿时长
3-6 weeks
期刊介绍: Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信